Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
4.200
-0.240 (-5.41%)
At close: Nov 20, 2024, 4:00 PM
4.400
+0.200 (4.76%)
Pre-market: Nov 21, 2024, 7:32 AM EST

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.252.370.020.01
Research & Development
2.171.570.830.13
Operating Expenses
10.423.940.850.14
Operating Income
-10.42-3.94-0.85-0.14
Interest Expense
-5.1-1.64--
EBT Excluding Unusual Items
-15.47-5.59-0.85-0.14
Other Unusual Items
-7.49-7.49--
Pretax Income
-22.96-13.07-0.85-0.14
Net Income
-22.96-13.07-0.85-0.14
Net Income to Common
-22.96-13.07-0.85-0.14
Shares Outstanding (Basic)
292727-
Shares Outstanding (Diluted)
292727-
Shares Change (YoY)
6.65%1.77%--
EPS (Basic)
-0.79-0.48-0.03-
EPS (Diluted)
-0.79-0.48-0.03-
Free Cash Flow
-5.55-3.86-0.47-0.12
Free Cash Flow Per Share
-0.19-0.14-0.02-
EBIT
-10.42-3.94-0.85-0.14
Source: S&P Capital IQ. Standard template. Financial Sources.